EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus

Kristen M Marks, Minhee Kang, Triin Umbleja, Anchalee Avihingsanon, Patcharaphan Sugandhavesa, Andrea L Cox, Karen Vigil, Hugo Perazzo, Jennifer C Price, Leolin Katsidzira, Christina Vernon, Beverly Alston-Smith und 2 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad201 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Kristen M Marks und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Hepatitis B virus, Hepatitis B. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior hepatitis B virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusHepatitis BHumansHIVToll-Like Receptor 9Hepatitis B VaccinesAdjuvants, ImmunologicHepatitis B AntibodiesHepatitis B Surface Antigens

Stichwörter der Autor:innen

HIVHepB-CpGHeplisav-Bhepatitis Bvaccine

Substanzen

Toll-Like Receptor 9Hepatitis B VaccinesAdjuvants, ImmunologicHepatitis B AntibodiesHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.
  • Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • HIV-NAT, Thai Red Cross AIDS Research Centre and CE in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
  • Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
  • Division of Infectious Diseases, McGovern Medical School, University of Texas, Houston, Texas, USA.

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Marks, K. M., Kang, M., Umbleja, T., Avihingsanon, A., Sugandhavesa, P., Cox, A. L., Vigil, K., Perazzo, H., Price, J. C., Katsidzira, L., Vernon, C., Alston-Smith, B., Sherman, K. E., & ACTG 5379 Study Team (2023). Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad201

Vancouver

Marks KM, Kang M, Umbleja T, Avihingsanon A, Sugandhavesa P, Cox AL, et al. Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad201

BibTeX
@article{Marks2023,
  author = {Marks, Kristen M and Kang, Minhee and Umbleja, Triin and Avihingsanon, Anchalee and Sugandhavesa, Patcharaphan and Cox, Andrea L and Vigil, Karen and Perazzo, Hugo and Price, Jennifer C and Katsidzira, Leolin and Vernon, Christina and Alston-Smith, Beverly and Sherman, Kenneth E and ACTG 5379 Study Team, ACTG 5379 Study Team},
  title = {Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad201}
}
Kostenlos starten →